Redirection of Human Autoreactive T-Cells Upon Interaction With Dendritic Cells Modulated by TX527, an Analog of 1,25 Dihydroxyvitamin D3
Redirection of Human Autoreactive T-Cells Upon Interaction With Dendritic Cells Modulated by TX527, an Analog of 1,25 Dihydroxyvitamin D 3 Astrid G.S. van Halteren 1 , Evelyne van Etten 2 , Esther C. de Jong 3 , Roger Bouillon 2 , Bart O. Roep 1 and Chantal Mathieu 2 1 Department of Immunohematology...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2002-07, Vol.51 (7), p.2119-2125 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Redirection of Human Autoreactive T-Cells Upon Interaction With Dendritic Cells Modulated by TX527, an Analog of 1,25 Dihydroxyvitamin
D 3
Astrid G.S. van Halteren 1 ,
Evelyne van Etten 2 ,
Esther C. de Jong 3 ,
Roger Bouillon 2 ,
Bart O. Roep 1 and
Chantal Mathieu 2
1 Department of Immunohematology and Blood Transfusion, Leids Universitair Medisch Centrum, Leiden, the Netherlands
2 Laboratory for Experimental Medicine and Endocrinology (LEGENDO), Katholieke Universiteit Leuven, Leuven, Belgium
3 Department of Cell Biology and Histology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
Abstract
The active form of vitamin D 3 , 1α,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), is a potent immunomodulator known to affect T-cells through targeting antigen-presenting cells such as dendritic cells
(DCs). We studied the effects of a novel nonhypercalcemic 1,25(OH) 2 D 3 analog, TX527, on DC differentiation, maturation, and function with respect to stimulation of a committed human GAD65-specific
autoreactive T-cell clone. Continuous addition of TX527 impaired interleukin (IL)-4 and granulocyte/macrophage colony-stimulating
factor (GM-CSF)-driven DC differentiation as well as lipopolysaccharide (LPS) and interferon-γ (IFN-γ)-induced maturation
into Th1-promoting DC (DC1), as characterized by marked changes in DC morphology and abrogation of IL-12p70 release upon CD40
ligation. Addition of TX527 during maturation did not affect DC morphology but significantly changed DC cytokine profiles.
The potential of treated DCs to alter the response pattern of committed autoreactive T-cells was found to depend on the timing
of TX527 exposure. Continuously TX527-treated DCs significantly inhibited T-cell proliferation and blocked IFN-γ, IL-10, but
not IL-13 production, whereas DCs treated during maturation failed to inhibit T-cell proliferation but affected IL-10 and
IFN-γ production. Collectively, we provide evidence that nonhypercalcemic TX527 is a potent in vitro DC modulator, yielding
DCs with the potential to change cytokine responses of committed autoreactive T-cells.
Footnotes
Address correspondence and reprint requests to Dr. B.O. Roep, Department of Immunohematology and Blood Transfusion, Leids
Universitair Medisch Centrum, E3Q, LUMC, P.O. Box 9600, 2300 RC Leiden, the Netherlands. E-mail: A.G.S.van_Halteren{at}lumc.nl .
Received for publication 16 November 2001 and accepted in revised form 21 February 2002.
1,25(OH) 2 D 3 , 1α,25-dihydroxyvita |
---|---|
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/diabetes.51.7.2119 |